Pfanstiehl Inc. is a US based cGMP Manufacturer of High Purity, High Quality, Low Endotoxin and Low Metal components such as Trehalose, Sucrose, Mannitol, Maltose, Galactose (non-animal), Mannose and Amino Acids such as Arginine, Histidine, Methionine and Glutamine for Biologics, Biosimilars, Vaccines, Cell Culture Media and Injectables (liquid & lyo) located in Waukegan, Illinois, USA. These products are utilized as critical stabilization components or process and upstream ingredients in many approved and marketed Biopharmaceuticals worldwide.

New Launches: Methionine (M168) and Glutamine (G167)

Pfanstiehl can provide full technical as well as regulatory support for our products incld. DMF filings in USA as well as in China and has tremendous manufacturing capacity for these critical biopharma ingredients.  All of Pfanstiehl’s products are multi-compendial and having industry leading quality specifications. Pfanstiehl has been in operation since 1919, focusing on both Biopharmaceutical excipients / critical components & Pharmaceutical HPAPIs / APIs (generic and on contract manufacturing base). Pfanstiehl specializes in isolation, purification, custom synthesis and scale-up development of regulated, high purity and low endotoxin Injectable Formulation Ingredients, Pharmaceutical Intermediates and Active Pharmaceutical Ingredients, in gram to multi-ton commercial quantities.

Pfanstiehl, Inc.
1219 Glen Rock Avenue
Waukegan, IL 60085-6230

USA Telephone: +1 847-623-0370
Toll Free Number: +1 800-383-0126
Europe Telephone: +41 41 755 40 54

Email: cs@pfanstiehl.com
Website: www.pfanstiehl.com

Go to article: Home | Digital dilemma in UK life sciences job marketGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: DatwylerGo to article: CytivaGo to article: bioMérieux Company InsightGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: Trends & InsightGo to article: PfanstiehlGo to article: SyntegonGo to article: In DepthGo to article: UK life sciences grapple with the job market’s digital dilemma Go to article: Telemedicine struggles to overcome diversity challenges in dermatology trials Go to article: Cancer treatment uncertainty: European nations struggle with drug shortages Go to article: From Europe to Latin America: Driving access to affordable biosimilars Go to article: Q&A: How the Henrietta Lacks settlement challenges biotech's view on ethics Go to article: Generative AI has the potential to revolutionise drug discovery Go to article: European PFAS ban would burden drug companies and packagers Go to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: Foreword: unlocking robotics’ full potential Go to article: An introduction to robotics Go to article: A history of robotics  Go to article: The impact of robotics on the healthcare sector Go to article: Case studies: robotics in the pharmaceutical industry Go to article: Latest news: robotics in pharmaGo to article: Robotics: transforming cell and gene therapy manufacturingGo to article: Robotics innovation: Leading companies in microneedles for transdermal drug delivery Go to article: Deal activity related to robotics in the pharmaceutical industry since 2020 Go to article: Robotics hiring trends in the global pharmaceutical industry since 2020 Go to article: Robotics patent applications in the global pharmaceutical industry since 2020 Go to article: Mentions of robotics in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Sponsored SupplementsGo to article: NiproGo to article: Watson MarlowGo to article: ListingsGo to article: EventsGo to article: AwardsGo to article: Buyer's GuidesGo to article: Next issue